5 unknown. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 5 |
| Phase 1 | 1 | Unknown 1 |
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression Selinexor combined with Prednisone, Etoposide, and Lenalidomide - DLBCL | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 67 | 2022-10-01 | 2022-08-19 |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma Orelabrutinib and Gemox - DLBCL | Phase 2 | Unknown | Sun Yat-sen University | 77 | 2022-07-01 | 2022-07-08 |
| Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL Camrelizumab - Primary Extranodal Lymphoma, DLBCL | Phase 2 | Unknown | Sun Yat-sen University | 30 | 2022-06-01 | 2022-04-07 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Ibrutinib Combined With Rituximab - DLBCL, MYD88 Gene Mutation | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2021-10-01 | 2021-08-06 |
| R2-CHOP in Untreated DEL-DLBCL:An Open-lable,Multicenter,Phase II Study R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide,hydroxyldaunorubicin,Vincristine,Prednisone)) - DLBCL | Phase 2 | Unknown | Sun Yat-sen University | 80 | 2021-04-10 | 2021-04-13 |
Recurrence (2) · Lymphoma (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Prednisone (2) · Rituximab (2) · Cyclophosphamide (1) · Doxorubicin (1) · Etoposide (1) · Lenalidomide (1) · Vincristine (1) · camrelizumab (1) · orelabrutinib (1)
Sun Yat-sen University (3) · Chinese Academy of Medical Sciences (1) · The Affiliated Hospital of Qingdao University (1)
China (2)
Huiqiang Huang, professor (1) · Yuankai Shi, M.D. (1) · Zhiming Li, Dr. (1)